The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).
Ana De Jesus-Acosta
No relevant relationships to disclose
Peter J. O'Dwyer
No relevant relationships to disclose
Ramesh K. Ramanathan
No relevant relationships to disclose
Daniel D. Von Hoff
No relevant relationships to disclose
Anirban Maitra
No relevant relationships to disclose
Zeshaan Rasheed
No relevant relationships to disclose
Lei Zheng
No relevant relationships to disclose
N. V. Rajeshkumar
No relevant relationships to disclose
Dung T. Le
No relevant relationships to disclose
Antje Hoering
No relevant relationships to disclose
Vanessa Bolejack
No relevant relationships to disclose
Shinichi Yabuuchi
No relevant relationships to disclose
Daniel A. Laheru
No relevant relationships to disclose